Dapagliflozin is an orally available SGLT2 inhibitor with an insulin independent mechanism of action and a lower risk of hypoglycemia than with conventional antidiabetic agents such as sulfonylureas and insulin. This evidence concerns the gene INS and Hypoglycemia.